Global Rabies Monoclonal Antibody Market Growth (Status and Outlook) 2024-2030

Global Rabies Monoclonal Antibody Market Growth (Status and Outlook) 2024-2030

According to this study, the global Rabies Monoclonal Antibody market size will reach US$ million by 2030.

Rabies monoclonal antibody (RMAb) is a type of antibody specifically targeted against the rabies virus, used for post-exposure prophylaxis.

The market for rabies monoclonal antibody is driven by its applications in rabies post-exposure treatment as part of rabies immunization protocols. RMAb is used in combination with the rabies vaccine to provide passive immunity against the virus. As rabies prevention and treatment continue to be essential public health measures, the market for rabies monoclonal antibody is expected to continue.

This report presents a comprehensive overview, market shares, and growth opportunities of Rabies Monoclonal Antibody market by product type, application, key players and key regions and countries.

Segmentation by product type:
Category II Exposure
Category III Exposure

Segmentation by Application:
Adult
Children

This report also splits the market by region:
United States
China
Europe
Other regions:
Japan
South Korea
Southeast Asia
Rest of world

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:
Serum Institute of India
NCPC
Crucell
Zydus
Synermore Biologics

Please note: The report will take approximately 2 business days to prepare and deliver.